Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for SYRE

Stock Name	Spyre Therapeutics Inc.
Ticker	SYRE(USD) NASDAQ
TYPE	Common Stock
Country	USA

Show aggregate SYRE holdings

News associated with SYRE

Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to “Hold” Rating: Wall Street Zen upgraded shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday. Separately, Wedbush reiterated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 6th. Two […] - 2025-09-09 02:57:04
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $53.40: Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price […] - 2025-09-08 02:32:51
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $53.40 Average PT from Analysts: Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year […] - 2025-08-14 02:31:05
XTX Topco Ltd Acquires Shares of 28,499 Spyre Therapeutics, Inc. (NASDAQ:SYRE): XTX Topco Ltd acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the first quarter, Holdings Channel reports. The institutional investor acquired 28,499 shares of the company’s stock, valued at approximately $460,000. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the […] - 2025-08-08 04:38:55
The Math Shows SCHA Can Go To $31: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38
Victory Capital Management Inc. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE): Victory Capital Management Inc. decreased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 251,846 shares of the company’s stock after selling 16,230 shares during the quarter. Victory Capital Management Inc.’s […] - 2025-07-28 05:02:49
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts: Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price […] - 2025-07-17 05:10:58
122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbH: Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 122,153 shares of the company’s stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% […] - 2025-06-03 05:35:02
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 22,741 shares of the company’s stock after acquiring an additional 916 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Spyre Therapeutics […] - 2025-05-30 04:48:57
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57: Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average […] - 2025-05-06 02:32:52
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Barclays PLC: Barclays PLC lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 16.7% in the fourth quarter, Holdings Channel reports. The firm owned 123,071 shares of the company’s stock after acquiring an additional 17,604 shares during the period. Barclays PLC’s holdings in Spyre Therapeutics were worth $2,866,000 as of its most recent filing […] - 2025-04-30 05:15:05
Legal & General Group Plc Has $873,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE): Legal & General Group Plc grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,490 shares of the company’s stock after purchasing an additional 4,824 shares during the quarter. […] - 2025-04-28 04:56:53
Vanguard Group Inc. Purchases 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE): Vanguard Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 13.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,846,473 shares of the company’s stock after acquiring an additional 330,553 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Spyre Therapeutics worth $66,266,000 as of […] - 2025-04-11 05:40:57
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Average Price Target from Brokerages: Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price […] - 2025-04-11 02:54:51
Corebridge Financial Inc. Sells 1,299 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE): Corebridge Financial Inc. lowered its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 7.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,213 shares of the company’s stock after selling 1,299 shares during the period. Corebridge Financial Inc.’s holdings in Spyre Therapeutics […] - 2025-04-10 04:49:04
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Wellington Management Group LLP: Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,604,508 shares of the company’s stock after acquiring an additional 97,308 shares during the quarter. Wellington Management Group LLP’s holdings in Spyre Therapeutics were worth $37,353,000 […] - 2025-04-07 06:35:09
Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE): Schroder Investment Management Group bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 113,620 shares of the company’s stock, valued at approximately $2,561,000. Schroder Investment Management Group owned about 0.22% of Spyre […] - 2025-04-07 05:10:58
Natixis Advisors LLC Invests $403,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE): Natixis Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the fourth quarter, Holdings Channel reports. The firm bought 17,300 shares of the company’s stock, valued at approximately $403,000. Several other large investors have also added to or reduced their stakes in SYRE. Barclays PLC increased its holdings in […] - 2025-03-28 06:04:54
Wolfe Research Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE): Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 46.74% from the company’s previous close. Several other equities […] - 2025-03-20 04:22:57
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Analysts: Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-03-14 04:25:02

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SYRE holdings

Date	Number of SYRE Shares Held	Base Market Value of SYRE Shares	Local Market Value of SYRE Shares	Change in SYRE Shares Held	Change in SYRE Base Value	Current Price per SYRE Share Held	Previous Price per SYRE Share Held
2025-09-26 (Friday)	24,066	USD 390,832	USD 390,832
2025-09-25 (Thursday)	24,066	USD 375,670	USD 375,670	0	USD -33,452	USD 15.61	USD 17
2025-09-24 (Wednesday)	24,066	USD 409,122	USD 409,122
2025-09-17 (Wednesday)	23,910	USD 359,846	USD 359,846	0	USD 5,500	USD 15.05	USD 14.82
2025-09-16 (Tuesday)	23,910	USD 354,346	USD 354,346
2025-09-12 (Friday)	23,754	USD 371,750	USD 371,750
2025-09-11 (Thursday)	23,754	USD 384,815	USD 384,815

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SYRE by Blackrock for IE00B3VWM098

Show aggregate share trades of SYRE

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -78 16.780* 19.90 Profit of 1,552 on sale
2025-07-31 BUY 234 16.970* 19.94
2025-06-30 SELL -156 14.970* 20.42 Profit of 3,186 on sale
2025-06-25 SELL -78 15.720* 20.52 Profit of 1,601 on sale
2025-06-20 SELL -156 15.010* 20.64 Profit of 3,220 on sale
2025-05-23 BUY 78 15.010* 21.38
2025-05-19 SELL -78 14.880* 21.60 Profit of 1,684 on sale
2025-05-15 SELL -234 14.540* 21.71 Profit of 5,081 on sale
2025-05-12 SELL -78 14.930* 21.90 Profit of 1,708 on sale
2025-05-09 SELL -78 14.100* 21.97 Profit of 1,714 on sale
2025-04-30 SELL -78 15.230* 22.52 Profit of 1,757 on sale
2025-04-24 SELL -156 14.930* 22.84 Profit of 3,563 on sale
2025-04-17 SELL -78 12.670* 23.34 Profit of 1,820 on sale
2025-04-15 SELL -234 12.710* 23.57 Profit of 5,516 on sale
2025-04-14 SELL -234 13.020* 23.69 Profit of 5,543 on sale
2025-04-09 SELL -312 13.370* 24.07 Profit of 7,510 on sale
2025-04-07 SELL -546 12.390* 24.35 Profit of 13,294 on sale
2025-04-04 BUY 6,017 12.790* 24.48
2025-03-31 BUY 57 16.135* 24.81
2025-03-19 SELL -114 18.400* 25.54 Profit of 2,911 on sale
2025-03-14 SELL -342 18.040* 25.85 Profit of 8,840 on sale
2025-03-13 SELL -114 18.030* 25.96 Profit of 2,959 on sale
2025-03-12 SELL -1,938 18.880* 26.06 Profit of 50,507 on sale
2025-03-07 SELL -114 19.490* 26.39 Profit of 3,008 on sale
2025-03-06 SELL -171 20.500* 26.48 Profit of 4,528 on sale
2025-03-03 SELL -57 17.940* 26.86 Profit of 1,531 on sale
2025-02-28 SELL -342 19.700* 26.98 Profit of 9,227 on sale
2025-02-26 SELL -57 19.000* 27.26 Profit of 1,554 on sale
2025-02-25 SELL -171 20.650* 27.37 Profit of 4,681 on sale
2025-02-18 BUY 285 22.070* 27.89
2025-02-13 BUY 57 22.680* 28.20
2025-02-12 BUY 57 23.270* 28.30
2025-02-11 BUY 171 22.150* 28.42
2025-02-06 BUY 513 23.860* 28.78
2025-01-27 BUY 57 20.820* 30.14
2024-12-30 BUY 285 22.540* 31.07
2024-12-06 BUY 228 27.080* 31.50
2024-12-05 BUY 57 25.550* 31.70
2024-12-04 BUY 285 27.990* 31.84
2024-11-29 BUY 285 28.430* 32.32
2024-11-27 BUY 228 27.750* 32.72
2024-11-26 BUY 57 27.830* 32.94
2024-11-25 BUY 4,228 27.810* 33.19
2024-11-21 BUY 220 27.000* 33.80
2024-11-20 BUY 132 27.500* 34.15
2024-11-18 BUY 528 28.670* 34.95
2024-11-12 BUY 352 35.820* 34.89
2024-11-08 BUY 220 39.575* 34.56
2024-11-07 BUY 660 37.690* 34.32
2024-11-06 BUY 88 37.480* 34.05
2024-10-31 BUY 44 32.530* 33.88
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-78	16.780*	19.90 Profit of 1,552 on sale
2025-07-31	BUY	234	16.970*	19.94
2025-06-30	SELL	-156	14.970*	20.42 Profit of 3,186 on sale
2025-06-25	SELL	-78	15.720*	20.52 Profit of 1,601 on sale
2025-06-20	SELL	-156	15.010*	20.64 Profit of 3,220 on sale
2025-05-23	BUY	78	15.010*	21.38
2025-05-19	SELL	-78	14.880*	21.60 Profit of 1,684 on sale
2025-05-15	SELL	-234	14.540*	21.71 Profit of 5,081 on sale
2025-05-12	SELL	-78	14.930*	21.90 Profit of 1,708 on sale
2025-05-09	SELL	-78	14.100*	21.97 Profit of 1,714 on sale
2025-04-30	SELL	-78	15.230*	22.52 Profit of 1,757 on sale
2025-04-24	SELL	-156	14.930*	22.84 Profit of 3,563 on sale
2025-04-17	SELL	-78	12.670*	23.34 Profit of 1,820 on sale
2025-04-15	SELL	-234	12.710*	23.57 Profit of 5,516 on sale
2025-04-14	SELL	-234	13.020*	23.69 Profit of 5,543 on sale
2025-04-09	SELL	-312	13.370*	24.07 Profit of 7,510 on sale
2025-04-07	SELL	-546	12.390*	24.35 Profit of 13,294 on sale
2025-04-04	BUY	6,017	12.790*	24.48
2025-03-31	BUY	57	16.135*	24.81
2025-03-19	SELL	-114	18.400*	25.54 Profit of 2,911 on sale
2025-03-14	SELL	-342	18.040*	25.85 Profit of 8,840 on sale
2025-03-13	SELL	-114	18.030*	25.96 Profit of 2,959 on sale
2025-03-12	SELL	-1,938	18.880*	26.06 Profit of 50,507 on sale
2025-03-07	SELL	-114	19.490*	26.39 Profit of 3,008 on sale
2025-03-06	SELL	-171	20.500*	26.48 Profit of 4,528 on sale
2025-03-03	SELL	-57	17.940*	26.86 Profit of 1,531 on sale
2025-02-28	SELL	-342	19.700*	26.98 Profit of 9,227 on sale
2025-02-26	SELL	-57	19.000*	27.26 Profit of 1,554 on sale
2025-02-25	SELL	-171	20.650*	27.37 Profit of 4,681 on sale
2025-02-18	BUY	285	22.070*	27.89
2025-02-13	BUY	57	22.680*	28.20
2025-02-12	BUY	57	23.270*	28.30
2025-02-11	BUY	171	22.150*	28.42
2025-02-06	BUY	513	23.860*	28.78
2025-01-27	BUY	57	20.820*	30.14
2024-12-30	BUY	285	22.540*	31.07
2024-12-06	BUY	228	27.080*	31.50
2024-12-05	BUY	57	25.550*	31.70
2024-12-04	BUY	285	27.990*	31.84
2024-11-29	BUY	285	28.430*	32.32
2024-11-27	BUY	228	27.750*	32.72
2024-11-26	BUY	57	27.830*	32.94
2024-11-25	BUY	4,228	27.810*	33.19
2024-11-21	BUY	220	27.000*	33.80
2024-11-20	BUY	132	27.500*	34.15
2024-11-18	BUY	528	28.670*	34.95
2024-11-12	BUY	352	35.820*	34.89
2024-11-08	BUY	220	39.575*	34.56
2024-11-07	BUY	660	37.690*	34.32
2024-11-06	BUY	88	37.480*	34.05
2024-10-31	BUY	44	32.530*	33.88

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SYRE

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	150,549	0	167,626	89.8%
2025-09-18	178,648	30	220,252	81.1%
2025-09-17	159,119	0	352,783	45.1%
2025-09-16	184,703	0	266,497	69.3%
2025-09-15	299,480	0	417,886	71.7%
2025-09-12	81,490	51	168,746	48.3%
2025-09-11	112,777	0	279,764	40.3%
2025-09-10	54,522	0	89,091	61.2%
2025-09-09	37,286	0	66,996	55.7%
2025-09-08	61,946	0	79,865	77.6%
2025-09-05	67,335	0	81,173	83.0%
2025-09-04	96,061	0	191,418	50.2%
2025-09-03	69,863	0	85,048	82.1%
2025-09-02	70,994	262	126,487	56.1%
2025-08-29	90,175	0	133,877	67.4%
2025-08-28	41,761	0	83,861	49.8%
2025-08-27	98,551	830	114,394	86.2%
2025-08-26	86,505	200	129,151	67.0%
2025-08-25	81,354	0	129,791	62.7%
2025-08-22	128,306	1,294	195,186	65.7%
2025-08-21	177,099	0	235,899	75.1%
2025-08-20	292,175	63	329,030	88.8%
2025-08-19	194,123	0	236,211	82.2%
2025-08-18	135,975	0	161,814	84.0%
2025-08-15	64,986	0	76,347	85.1%
2025-08-14	48,287	0	68,692	70.3%
2025-08-13	90,663	0	110,588	82.0%
2025-08-12	47,259	11	58,736	80.5%
2025-08-11	125,593	0	144,626	86.8%
2025-08-08	74,973	8	91,136	82.3%
2025-08-07	101,536	0	117,094	86.7%
2025-08-06	128,728	120	167,975	76.6%
2025-08-05	80,574	0	108,628	74.2%
2025-08-04	86,996	0	218,524	39.8%
2025-08-01	107,059	0	187,161	57.2%
2025-07-31	111,323	5	128,337	86.7%
2025-07-30	311,506	16	340,840	91.4%
2025-07-29	86,541	0	99,797	86.7%
2025-07-28	112,469	7	156,419	71.9%
2025-07-25	198,182	18	543,012	36.5%
2025-07-24	106,594	118	290,774	36.7%
2025-07-23	117,057	0	135,185	86.6%
2025-07-22	86,970	560	141,880	61.3%
2025-07-21	98,609	0	111,720	88.3%
2025-07-18	100,106	0	106,286	94.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE